Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780433 | 0.93 | KMT2A (0.58) | SIRT6POLBKMT2AHTR1AMAPT | |
| SCHEMBL5784690 | 0.92 | SIRT6 (0.71) | SIRT6POLBKMT2AHTR1AMAPT | |
| SCHEMBL12431530 | 0.86 | MAPT (0.70) | SIRT6POLBKMT2AHTR1AMAPT | |
| SCHEMBL6151796 | 0.84 | SIRT6 (0.64) | SIRT6POLBKMT2AHTR1AMAPT | |
| SCHEMBL4628534 | 0.84 | SIRT6 (0.64) | SIRT6POLBKMT2AHTR1AMAPT | |
| SCHEMBL4248033 | 0.84 | SIRT6 (0.64) | SIRT6POLBKMT2AHTR1AMAPT | |
| SCHEMBL1045292 | 0.84 | SIRT6 (0.69) | SIRT6POLBKMT2AHTR1AMAPT | |
| SCHEMBL15599506 | 0.84 | POLB (0.64) | SIRT6POLBKMT2AHTR1AMAPT | |
| SCHEMBL2717022 | 0.84 | SIRT6 (0.64) | SIRT6POLBKMT2AHTR1AMAPT | |
| SCHEMBL10359671 | 0.83 | KCNJ1 (0.82) | SIRT6POLBHTR1AKCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| CN-119923391-A | Targeted protein degradation of PARP14 for use in therapy | 艾伯维新加坡运营私人有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | ABBVIE BIOTECHNOLOGY LTD (BM) | 2024-03-28 | — | — | US | disclosed |
| WO-2024026081-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20050107374-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | SIRT6 2716/4885POLB 2005/4885KMT2A 3699/4885 |
| US-20050107374-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | SIRT6 3760/4885POLB 3889/4885KMT2A 3518/4885 |
| US-20240101540-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | PARP14, PARP15, PARP16 | SIRT6 239/4885POLB 952/4885KMT2A 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.